Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
But, as stated in your note, the warrants are for common stock exercisable at $.25. The 29 units with 400K share warrants would add about 12MM shares to common stock if exercised. Not alot of dilution but more dilution all the same.
I'm hoping we get a real update before the end of the year and the price stays above a buck.
Could be a delay in the Mayo engagement because of a surge in COVID cases among the MAYO staff.
https://www.beckershospitalreview.com/workforce/1-200-midwest-mayo-clinic-workers-sidelined-by-covid-19.html
The price seemed to fluctuate in a range between .13 and .20 for the past few months but there appears to be a market shift with a new price range. I don't think the price drops much below 20 cents so you may not get your wish for loading up at 14 cents. Construction plans probably get announced by January, after which the price range continues to march higher.
Looks good in the bench testing as well... but, to your point, they have to be able to shrink it down to a wearable size to prove the technology.
There's still time for KNWN... G7 won't be available until the second half of 2021. Although the G7 is an improvement over G6 it still has issues. It's expensive and only lasts 7 days. Also, it has to be worn on the arm or torso and the adhesive causes irritation for some people.
DEXCOM's G7 will be the most advanced CGM device on the market in 2021 and the KNWN platform will be a quantum leap in CGM technology over the G7. In addition, the KNWN device can be used for a wide range of large-molecule detection applications.
I agree that this is big... there seems to be alot of enthusiasm for ABML over on Stocktwits. Good find.
Good one... another short busted trying to spread misinformation. Only a few thousand more shorts to go.
It's comical that they released the 90%/70% number before truly vetting it. The fact that they had 90% effectiveness using a half-dose first followed by a full dose had most people scratching their heads.
It shows the folly of releasing scientific data through PR's.
Seems like alot of rookie mistakes...
- Not filing for fast track designation
- Not releasing preprints before submitting P1 paper for peer review
- Using a new device without proper certification
- Failing to lock in manufacturing agreements
You'd think this was their first rodeo. I guess they've taken their time on previous vaccines and just didn't believe this was a pandemic and urgency and flawless execution were critical.
Add to that the reluctance many will have to accepting an mRNA vaccine based on radically new technology which has no long-term testing. I think current estimates of 60% adoption for the PFE and MRNA vaccines are very high.
People have not really tuned in while the vaccines were still in development... when the vaccines start being offered then people will begin to pay attention and will learn about potential short and long term effects of mRNA vaccines. Many will not want to be guinea pigs for BP and the NIH.
Will be interested to hear if you have the same opinion 4 years from now... welcome to the Great Reset engineered by power hungry globalists thrilled to use the pandemic to advance their goals!
https://www.weforum.org/great-reset/
Science, Science, Science was a mantra designed to provide cover for their real intentions and people naively bought into the hype.
Why would they get rejected by Mayo? Didn't they basically hire Mayo to perform the study?
If you're worried about the price drops on large volumes, there were a number of people who bought large blocks of shares at 25 cents a couple of years ago. I suspect that some of the large share dumps are those folks lightening up their positions because of the expected changes to the tax laws next year. For them, selling at $1.50 or even $1.35 reflects a 400%-500% profit.
With Particle in the wings and the start of the Mayo study, I'm optimistic we'll see big news in the near future. Not sure if the news will come in time to sell before the onslaught of new taxes though.
Two reasons that INO will survive the vaccine wars are a superior platform that will be nimble in adapting to COVID mutations and a technology that won't introduce potential long-term adverse reactions in those being vaccinated.
https://www.zerohedge.com/medical/new-strains-covid-could-render-vaccines-completely-useless-and-2-dangerous-mutations-are
Actually, I don't think Trident is worried too much about the fish since there's not much environmental impact expected from Pebble. I think they are more worried about having to pay wages to compete with Pebble wages.
Not a battle for natural resources, but a battle for human resources. And Alaska residents will be the losers if Pebble is blocked.
Not all of Peter Shultz's recommendations are disasters, but a few have been. I think the common denominator in alot of the scams is Joe Salvani who has been the conduit for much of the convertible funding, leading to massive dilution.
Think carefully about investing in any company with links to Joe. Even though ABML had links to Joe I'm still invested... I'm optimistic we're moving in a direction that will be successful. Besides, I had bought alot of ABML at 3 cents and sold enough at 15+ cents so that I'm mostly playing with house money now.
I don't understand Ben Matone's statement:
They have been pretty quiet... could be a blackout before major news is announced.
I know that P1/P2 trials are underway in S. Korea and China... any idea on when they are planning to start P3 trials in either of those countries?
Also, what's the status of trials in Australia?
Thanks for the updates.
One possible reason this is a marathon that INO wins is the fact that the frequency of moderate and severe adverse events seem to increase with subsequent injections of mRNA vaccines. However, INO had no level 2 or 3 AE's for either the first or second injections of INO-4800.
Most experts agree that COVID immunity, like other coronaviruses, seems to wear off over time so that people may need to be vaccinated annually. Who will want to take an mRNA vaccine in the second round when a safe and effective alternative is available?
Your claim that INO will not produce a vaccine is based solely on history as your repeatedly remind us that INO hasn't produced a drug in their ~20 year research into DNA medicine. But, like all predictions based on history, you are looking out the rear view mirror to steer your car. This will work as long as the road ahead stays the same.
Your prediction may prove true, but longs here are betting that COVID has changed the map and INO's car could speed ahead while your car crashes.
It will be interesting to see where we end up in 12-18 months.
We are in the middle of a pandemic and Sorrento is surrounded by companies that have delivered on their promises in record time. Meanwhile, Sorrento keeps introducing new products into their pipeline and buying more companies but doesn't seem to be able to deliver on anything.
COVI-TRACK and COVI-TRACE were announced months ago and they were going to apply for an EUA in weeks... nothing but crickets from the company on these products. All we get are more announcements on future products.
Investors have written Sorrento off as a pump and dump and shorts have made boatloads of money off of this stock.
If there are safe and effective therapeutics (e.g., STI-2020) then I predict that we see a much higher proportion of the population refusing a rushed vaccine. The mRNA platform used in the Pfizer vaccine has never been approved for a drug, much less a vaccine. There are known short-term issues with this technology (i.e., a high percentage of adverse reactions) and, since it hasn't been widely tested, there are concerns about possible long-term issues such as triggering autoimmune diseases.
The fact that STI-2020 also appears to be a prophylactic makes it even more attractive. I won't be an early adopter for an unproven type of vaccine, especially if there are effective COVID treatments in place.
Since many people will resist taking a vaccine based on unproven technology, I still believe that therapeutics will be a big factor in recovery from COVID which is a positive for SRNE.
However, Henry Ji has not demonstrated an ability to deliver on promised timelines which is a negative for SRNE. COVI-TRACK and COVI-TRACE were supposed to be approved by now but, instead of news, all we get is crickets. This doesn't portend well for the antibody therapies that have been proposed.
As far as I can tell, Phil Boshua owns about 2M shares of KNWN and probably has a few million shares available through options/warrants. For small biotechs, there is alot of risk associated with the FDA approval process... I don't think Phil would have a problem cashing out today and leaving the 1.2M shares on the table. This is especially true since he will still be working on Particle which has tons of future profit potential.
If the deal is structured appropriately then "spinning" off the UBand would reap a large profit very quickly.
You could argue that they are leaving money on the table by not marketing the UBand themselves but, at the same time, they are avoiding the risk/hassle associated with entering a new market and competing with large established players like Dexcom and Abbott Labs.
They would also avoid the FDA approval process which is a potential minefield for small biotechs.
Since I didn't subscribe to the Particle investment I'm not privy to the current plans for Particle. Rumors from this board and elsewhere seem to suggest that KNWN will sell or license the medical applications (after the Mayo trial) and continue developing non-medical applications through Particle.
You mention a stock split but I'm not sure what happens to KNWN stock after these changes occur. Will KNWN still exist and continue to own Particle or does KNWN get sold off and the company is now known as Particle? Anyone have thoughts on what might happen?
earningswhispers.com shows earnings reporting on Friday 11/13 but it's not confirmed.
Actually, in the case of a tie it goes to the House where each state / delegation only gets one vote. In the unlikely event of a tie Trump is expected to win since he has more states.
Hopefully, in 2 months time, after Biden is inaugurated he will still be able to say the word "science" and remember Fauci's name. Let's hope that the person in charge at the point in time will rely on science and beef up testing.
As noted before, this stock is pretty thinly traded and bounces around alot for no apparent reason. Many on this board have probably been in for a few years and may have gotten it when KNWN was under $1 so they are comfortable riding out the ups and downs.
I think we'll see some great news in the next 2-3 months at which time the stock will probably explode. The technology is too revolutionary and they own the patents. I've got a limit order in to buy more on the dips. GLTA
Given the earnings call on Monday, I don't think we'll see a big drop this week... next Tuesday, however, could be a different story if they don't have significant news.
Any idea what "PHA" in the Lobbying Issues field means? Is this some sort of Public Health abbreviation?
I don't believe it will get to $20 until we have several full scale plants operating (3+ yrs from now). If we ramp up to $10M/mo of profit in 2021 (may be optimistic) then we're talking about a $1B market cap. Our big problem is the dilution... with 500M shares outstanding then we're probably only in the neighborhood of a $2 sp. This is still more than 10X from today's price so I'll be quite happy.
Given the comments by TSponberg on balanced buy/sells and the fact that the price recovered so quickly, I think "This is a Scam" and "Problems with Mayo" are off the table.
I didn't have funds available in my Roth to jump on the dip but will clear up some funds for possible dips next week.
Like others on this board I see massive potential and expect legacy wealth from this stock. Anything below $1.50 is an absolute steal!
Or it could be driven by the election volatility and some analysts advising people to take capital gains now in case of a Biden win.
Given the speculative nature of this stock, a couple of large holders selling their positions could spook weaker hands into a 40% drop in 2 days. Something similar happened on 12/31/2018 when KNWN dropped below $1 on a volume of almost 300K shares. There was never any explanation for the drop, only speculation that a few large holders were taking capital gains in 2018 that would be offset by some of their 4Q18 losses. The price bounced back right after New Years.
I'm planning on adding if the price continues to drop on Monday and Tuesday.
Isn't this how vaccines always work... they don't eliminate the virus, they just train our immune systems to fight it. Tell me if this is not true.
In the case of diseases like polio and smallpox, widespread vaccinations have halted contagion and the diseases ultimately disappeared.